<DOC>
	<DOC>NCT00262483</DOC>
	<brief_summary>To assess the safety of the combination of VX-950, Pegasys and Copegus in subjects with hepatitis C.</brief_summary>
	<brief_title>Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Infected with hepatitis C virus Contraindications to peginterferon or ribavirin therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>